For the pharmaceutical industry
Beyond treatment: new ways to understand how patients may respond.
DIASCI is researching how biosensing and AI could support biomarker follow-up over time. Monitoring therapeutic response is a research direction — it still depends on studies and validation.
Market opportunity
Understanding response remains a challenge
Therapeutic development, patient stratification and trial design depend on reliable biomarker information collected over time — often through costly or invasive methods.
- Need for frequent, less invasive biomarker data
- Stratification and response insights in clinical research
- Pressure to shorten development cycles
How DIASCI may contribute
Biosensors and biomarkers, combined with AI
DIONCO detects biological signals electrochemically; the AI layer is designed to interpret them. Together they may support future diagnostic follow-up.
- Investigation of biomarker monitoring related to therapeutic response
- Feasibility studies within your research programs
- The technology does not currently measure clinical response to treatment
Potential applications and expected benefits
Potential applications
Potential applicationBiomarker tracking
Follow selected biomarkers across time points in studies.
Response research
Investigate links between biomarker signals and therapy response.
Stratification support
Possible future input for patient selection in research.
Companion approaches
Long-term exploration of diagnostic follow-up alongside therapies.
Evidence and current stage
All pharmaceutical applications are research hypotheses. Any study requires protocol design, ethics approval and validation.
Biosensing platform
In development.
Therapeutic response monitoring
Development hypothesis, not a validated capability.
Clinical validation
Not yet performed.
DIONCO and the AI platform are in development. Preliminary, company-reported findings support further assessment; clinical and regulatory validation is still required. No product is currently approved or commercially available.
Possible collaboration models
Exploratory possibilities only. Any model depends on mutual interest, due diligence and formal agreements.
Pilot projects
Joint research and feasibility studies under agreed protocols.
Co-development
Developing applications around specific biomarkers or therapies.
Technology licensing
Potential technology licensing for defined uses.
Request a meeting
Request a Meeting with DIASCI
Tell us about your research or development program. We'll explore whether a joint study or partnership makes sense.